Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer

Medicine and Dentistry

• Microparticle 100%
• Docetaxel 55%
• Transurethral Resection 22%
• Bladder Tumor 22%
• Injection 22%
• Immune Checkpoint Inhibitor 22%
• Non Muscle Invasive Bladder Cancer 16%
• Patient 16%
• Drug Megadose 11%
• Follow up 11%
• Tumor Microenvironment 11%
• Recurrence Free Survival 11%
• Immunocompetent Cell 11%
• Therapeutic Procedure 11%
• Receptor 5%
• Low Drug Dose 5%
• Hazard Ratio 5%
• Surgery 5%
• Combination Therapy 5%
• Pharmacokinetics 5%
• Tumor Recurrence 5%
• Cytotechnology 5%
• CTLA-4 5%
• Cystoscopy 5%
• Cellular Infiltration 5%
• Enalapril Maleate 5%
• Intravesical Drug Administration 5%
• Analysis 5%
• Biopsy 5%
• Blood 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Docetaxel 55%
• Bladder Tumor 22%
• Non Muscle Invasive Bladder Cancer 16%
• Recurrence Free Survival 11%
• Tumor Microenvironment 11%
• Programmed Death-Ligand 1 11%
• Receptor 5%
• Pharmacokinetics 5%
• Enalapril Maleate 5%
• Tumor Recurrence 5%
• Cytotoxic T Lymphocyte Antigen 4 5%
• Bacilli 5%